CSPC Pharmaceutical Group Limited
1093.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$103.62B
Close$
$3.60
60.3% downside
Current Fair Value
60.3% downsideOvervalued by 60.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $103.62 Billion |
|---|---|
| Enterprise Value | $94.91 Billion |
| Dividend Yield | $0.29 (3.19%) |
| Earnings per Share | $0.33 |
| Beta | 0.71 |
| Outstanding Shares | 11,401,166,000 |
Return
| Return on Equity | 25.03% |
|---|---|
| Return on Assets | 16.81% |
| Return on Invested Capital | 31.94% |
Valuation & Multiples
| P/E Ratio | 11.9 |
|---|---|
| PEG | 0.74 |
| Price to Sales | 2.27 |
| Price to Book Ratio | 3.02 |
| Enterprise Value to Revenue | 1.95 |
| Enterprise Value to EBIT | 7.14 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$0.16
Average shareholder expectationRevenue Estimate
$15.44 B
Average shareholder expectationNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
$0.28
Average shareholder expectationRevenue Estimate
$15.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CSPC Pharmaceutical Group Limited.
18,626 employees
CEO: Lei Cai CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's ...